These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523 [TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079 [TBL] [Abstract][Full Text] [Related]
8. Growth of human melanocyte cultures supported by 12-O-tetradecanoylphorbol-13-acetate is mediated through protein kinase C activation. Arita Y; O'Driscoll KR; Weinstein IB Cancer Res; 1992 Aug; 52(16):4514-21. PubMed ID: 1643643 [TBL] [Abstract][Full Text] [Related]
9. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890 [TBL] [Abstract][Full Text] [Related]
10. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer. Ouerhani S; Elgaaied AB Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081 [TBL] [Abstract][Full Text] [Related]
11. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459 [TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Knobbe CB; Reifenberger J; Reifenberger G Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309 [TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses. Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220 [TBL] [Abstract][Full Text] [Related]
15. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions. Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771 [TBL] [Abstract][Full Text] [Related]
16. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547 [TBL] [Abstract][Full Text] [Related]
17. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Saldanha G; Potter L; Daforno P; Pringle JH Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595 [TBL] [Abstract][Full Text] [Related]
19. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447 [TBL] [Abstract][Full Text] [Related]
20. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Arnault JP; Mateus C; Escudier B; Tomasic G; Wechsler J; Hollville E; Soria JC; Malka D; Sarasin A; Larcher M; André J; Kamsu-Kom N; Boussemart L; Lacroix L; Spatz A; Eggermont AM; Druillennec S; Vagner S; Eychène A; Dumaz N; Robert C Clin Cancer Res; 2012 Jan; 18(1):263-72. PubMed ID: 22096025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]